Literature DB >> 23425079

Clinical features and etiology of Budd-Chiari syndrome in Chinese patients: a single-center study.

Delei Cheng1, Hao Xu, Zhao-Jun Lu, Rong Hua, Huan Qiu, Hongtao Du, Xinjian Xu, Jing Zhang.   

Abstract

BACKGROUND AND AIM: The clinical features and etiology of Budd-Chiari syndrome (BCS) vary from region to region, and there is lack of large sample studies about BCS in China. The aim of the present study was to study the clinical features and etiology of patients with incident BCS in China prospectively.
METHODS: A consecutive case series of patients with incident BCS who were diagnosed in the Affiliated Hospital of Xuzhou Medical College (Jiangsu, China) were enrolled from September 2010 to December 2011. All of the patients had continuous follow-ups to record the symptoms, body features, laboratory and radiology findings, and treatment methods through May 2012.
RESULTS: A total of 145 incident cases of BCS were identified. BCS was caused by hepatic venous obstruction in 31% of the patients, inferior vena cava obstruction in 6% of the patients, and 63% suffered from a combination of the two conditions. At least one etiological factor was present in 82% of the patients, with the most common being membranous obstruction (61%). Only 5% of the patients had myeloproliferative neoplasms with a JAK2 V617F mutation, and none of the patients had a factor V Leiden mutation. Eighteen months after a percutaneous transluminal angioplasty was performed, the survival rate and the asymptomatic survival rate were 99% (95% confidence interval, 95-100%) and 93% (95% confidence interval, 89-98%), respectively.
CONCLUSION: The most prevalent etiological factor for BCS in China is membranous obstruction. Moreover, most Chinese patients with chronic BCS are treated with percutaneous transluminal angioplasty and have an excellent clinical outcome.
© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23425079     DOI: 10.1111/jgh.12140

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  19 in total

1.  Studies on Budd-chiari syndrome complicated with hepatocellular carcinoma: most patients without inferior vena cava obstruction.

Authors:  Xiaowei Dang; Luhao Li; Suxin Li; Yafei Wang; Hai Li; Shaokai Xu; Peiqin Xu
Journal:  Int J Clin Exp Med       Date:  2015-06-15

2.  Combined thrombus aspiration and recanalization in treating Budd-Chiari syndrome with inferior vena cava thrombosis.

Authors:  Yu-Fei Fu; Hao Xu; Qian Wu; Qing-Qiao Zhang; Yan-Feng Cui; Ning Wei
Journal:  Radiol Med       Date:  2015-05-24       Impact factor: 3.469

Review 3.  Research status of Budd-Chiari syndrome in China.

Authors:  Xiaowei Dang; Luhao Li; Peiqin Xu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 4.  Selection of treatment modalities for Budd-Chiari Syndrome in China: a preliminary survey of published literature.

Authors:  Xing-Shun Qi; Wei-Rong Ren; Dai-Ming Fan; Guo-Hong Han
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

5.  Redefining Budd-Chiari syndrome: A systematic review.

Authors:  Naomi Shin; Young H Kim; Hao Xu; Hai-Bin Shi; Qing-Qiao Zhang; Jean Paul Colon Pons; Ducksoo Kim; Yi Xu; Fei-Yun Wu; Samuel Han; Byung-Boong Lee; Lin-Sun Li
Journal:  World J Hepatol       Date:  2016-06-08

6.  Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).

Authors:  Akash Shukla; Ananta Shreshtha; Amar Mukund; Chhagan Bihari; C E Eapen; Guohong Han; Hemant Deshmukh; Ian Homer Y Cua; Cosmas Rinaldi Adithya Lesmana; Mamun Al Meshtab; Masayoshi Kage; Roongruedee Chaiteeraki; Sombat Treeprasertsuk; Suprabhat Giri; Sundeep Punamiya; Valerie Paradis; Xingshun Qi; Yasuhiko Sugawara; Zaigham Abbas; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-07-08       Impact factor: 6.047

7.  Percutaneous recanalization for hepatic vein-type Budd-Chiari syndrome: long-term patency and survival.

Authors:  Yan-Feng Cui; Yu-Fei Fu; De-Chun Li; Hao Xu
Journal:  Hepatol Int       Date:  2015-10-23       Impact factor: 6.047

Review 8.  An Update on the Management of Budd-Chiari Syndrome.

Authors:  A Sharma; S N Keshava; A Eapen; E Elias; C E Eapen
Journal:  Dig Dis Sci       Date:  2020-07-20       Impact factor: 3.199

9.  The Significance of Serum CA-125 Elevation in Chinese Patients with Primary Budd-Chiari Syndrome: A Multicenter Study.

Authors:  De-Lei Cheng; Hao Xu; Wei-Fu Lv; Rong Hua; Hongtao Du; Qing-Qiao Zhang
Journal:  Gastroenterol Res Pract       Date:  2015-09-15       Impact factor: 2.260

Review 10.  Budd-Chiari Syndrome in China: A Systematic Analysis of Epidemiological Features Based on the Chinese Literature Survey.

Authors:  Wei Zhang; Xun Qi; Xitong Zhang; Hongying Su; Hongshan Zhong; Jingpu Shi; Ke Xu
Journal:  Gastroenterol Res Pract       Date:  2015-10-04       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.